Plain-English translation of NCT06694805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new way to treat HIV using long-acting injectable medications called cabotegravir and rilpivirine (). Instead of taking daily pills, participants would receive injections every 2 months. The trial is designed for people living with HIV whose virus is still detectable—meaning the virus levels haven't dropped low enough—even though they're taking oral (pill) medications.
Some people with HIV find that their daily pills aren't controlling the virus well enough, either because the medications aren't working as expected or because they're having trouble taking them consistently. This study explores whether this medication could offer a simpler, longer-lasting option that might be easier to stick with and more effective.
If you're assigned to receive the new treatment, you would get injections at your first visit and one month later, then continue with injections every 2 months for up to 24 months. If you're in the control group, you'll continue taking your current daily HIV pills for 6 months. Throughout the study, you'll have regular visits to check how well the treatment is working, assess any side effects, and share your experience with the medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States